东阳光长江药业此前发布截至2024年6月30日止6个月业绩，该集团期内取得营业额24.55亿元(人民币，下同);公司权益股东应占溢利6.85亿元;每股基本盈利0.78元。集团以胰岛素为代表的慢病线正在逐渐进入收获期，2024年上半年实现营业额1.8亿元，较去年同期大幅增长140.7%。Hec cj pharm (01558) rose nearly 4% in early trading, up 3.67% at the time of writing, to HKD 9.04, with a turnover of HKD 17.7639 million.
According to the Futubull app, Hec cj pharm (01558) rose nearly 4% in early trading, up 3.67% at the time of writing, to HKD 9.04, with a turnover of HKD 17.7639 million.
In terms of news, the Shanghai Stock Exchange and the Shenzhen Stock Exchange announced that 33 stocks under the Hong Kong Stock Connect will be included, including Hec cj pharm.
Hec cj pharm previously released its performance for the six months ended June 30, 2024, with a turnover of CNY 2.455 billion; the equity shareholders of the company accounted for a surplus of CNY 0.685 billion; and basic earnings per share of CNY 0.78. The group's chronic disease line, represented by insulin, is gradually entering the harvest period, achieving a turnover of CNY 0.18 billion in the first half of 2024, a significant increase of 140.7% compared to the same period last year.